{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:18:01Z","timestamp":1786119481147,"version":"build-2736575974"},"reference-count":59,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1097\/wco.0b013e32833cc968","type":"journal-article","created":{"date-parts":[[2010,7,22]],"date-time":"2010-07-22T05:41:59Z","timestamp":1279777319000},"page":"489-495","source":"Crossref","is-referenced-by-count":71,"title":["Autoimmune mediated neuromuscular junction defects"],"prefix":"10.1097","volume":"23","author":[{"given":"Maria Elena","family":"Farrugia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20210206","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/ana.20061","article-title":"Detection and characterization of MuSK antibodies in seronegative myasthenia gravis","volume":"55","author":"McConville","year":"2004","journal-title":"Ann Neurol"},{"key":"R2-8-20210206","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat Med"},{"key":"R3-8-20210206","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/brain\/awl095","article-title":"MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis","volume":"129","author":"Farrugia","year":"2006","journal-title":"Brain"},{"key":"R4-8-20210206","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/mus.21533","article-title":"Clinical findings in MuSK-antibody positive myasthenia gravis: a U.S. experience","volume":"41","author":"Pasnoor","year":"2010","journal-title":"Muscle Nerve"},{"key":"R5-8-20210206","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1212\/01.WNL.0000065882.63904.53","article-title":"Clinical aspects of MuSK antibody positive seronegative MG","volume":"60","author":"Sanders","year":"2003","journal-title":"Neurology"},{"key":"R6-8-20210206","doi-asserted-by":"crossref","first-page":"893","DOI":"10.2353\/ajpath.2007.070240","article-title":"Myasthenia gravis thymus: complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status","volume":"171","author":"Leite","year":"2007","journal-title":"Am J Pathol"},{"key":"R7-8-20210206","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1212\/01.wnl.0000339103.08830.86","article-title":"HLA class II allele analysis in MuSK-positive myasthenia gravis suggests a role for DQ5","volume":"72","author":"Bartoccioni","year":"2009","journal-title":"Neurology"},{"key":"R8-8-20210206","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1212\/01.wnl.0000218159.79769.5c","article-title":"Strong association of MuSK antibody-positive myasthenia gravis and HLA-DR14-DQ5","volume":"66","author":"Niks","year":"2006","journal-title":"Neurology"},{"key":"R9-8-20210206","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/ana.20341","article-title":"Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis","volume":"57","author":"Shiraishi","year":"2005","journal-title":"Ann Neurol"},{"key":"R10-8-20210206","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1365-2990.2008.00965.x","article-title":"Muscle histopathology in myasthenia gravis with antibodies against MuSK and AChR","volume":"35","author":"Martignago","year":"2009","journal-title":"Neuropathol Appl Neurobiol"},{"key":"R11-8-20210206","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.clinph.2006.03.028","article-title":"Neurophysiological and mitochondrial abnormalities in MuSK antibody seropositive myasthenia gravis compared to other immunological subtypes","volume":"117","author":"Rostedt Punga","year":"2006","journal-title":"Clin Neurophysiol"},{"key":"R12-8-20210206","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/ana.21371","article-title":"Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction","volume":"63","author":"Cole","year":"2008","journal-title":"Ann Neurol"},{"key":"R13-8-20210206","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.2353\/ajpath.2009.090040","article-title":"The effect of plasma from muscle-specific tyrosine kinase myasthenia patients on regenerating endplates","volume":"175","author":"ter Beek","year":"2009","journal-title":"Am J Pathol"},{"key":"R14-8-20210206","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/brain\/awn092","article-title":"IgG1 antibodies to acetylcholine receptors in \u2018seronegative\u2019 myasthenia gravis","volume":"131","author":"Leite","year":"2008","journal-title":"Brain"},{"key":"R15-8-20210206","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1471-2377-10-46","article-title":"A systematic review of population based epidemiological studies in myasthenia gravis.","volume":"10","author":"Carr","year":"2010","journal-title":"BMC Neurology"},{"key":"R16-8-20210206","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1212\/WNL.0b013e3181ad53c2","article-title":"Seropositive myasthenia gravis: a nationwide epidemiologic study","volume":"73","author":"Heldal","year":"2009","journal-title":"Neurology"},{"key":"R17-8-20210206","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1136\/jnnp.74.8.1105","article-title":"Evidence of underdiagnosis of myasthenia gravis in older people","volume":"74","author":"Vincent","year":"2003","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R18-8-20210206","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/nature06066","article-title":"An IRF8-binding promoter variant and AIRE control CHRNA1 promiscuous expression in thymus","volume":"448","author":"Giraud","year":"2007","journal-title":"Nature"},{"key":"R19-8-20210206","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jneuroim.2009.02.009","article-title":"Interleukin-10 promoter polymorphisms in myasthenia gravis","volume":"210","author":"Alseth","year":"2009","journal-title":"J Neuroimmunol"},{"key":"R20-8-20210206","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jneuroim.2009.08.018","article-title":"Expanded TCR Vbeta subsets of CD8(+) T-cells in late-onset myasthenia gravis: novel parallels with thymoma patients","volume":"216","author":"Tackenberg","year":"2009","journal-title":"J Neuroimmunol"},{"key":"R21-8-20210206","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1212\/WNL.0b013e3181d7d884","article-title":"Detection of poliovirus-infected macrophages in thymus of patients with myasthenia gravis","volume":"74","author":"Cavalcante","year":"2010","journal-title":"Neurology"},{"key":"R22-8-20210206","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/MRR.0b013e32831e4587","article-title":"Disability and functional profiles of patients with myasthenia gravis measured with ICF classification","volume":"32","author":"Leonardi","year":"2009","journal-title":"Int J Rehabil Res"},{"key":"R23-8-20210206","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.3109\/09638280902893634","article-title":"Identification of international classification of functioning, disability and health relevant categories to describe functioning and disability of patients with myasthenia gravis","volume":"31","author":"Leonardi","year":"2009","journal-title":"Disabil Rehabil"},{"key":"R24-8-20210206","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1002\/mus.21016","article-title":"Disease-specific measure of quality of life for myasthenia gravis","volume":"38","author":"Mullins","year":"2008","journal-title":"Muscle Nerve"},{"key":"R25-8-20210206","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1002\/mus.21053","article-title":"Less is more, or almost as much: a 15-item quality-of-life instrument for myasthenia gravis","volume":"38","author":"Burns","year":"2008","journal-title":"Muscle Nerve"},{"key":"R26-8-20210206","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/mus.21609","article-title":"Construct and concurrent validation of the MG-QOL15 in the practice setting","volume":"41","author":"Burns","year":"2010","journal-title":"Muscle Nerve"},{"key":"R27-8-20210206","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1002\/mus.21185","article-title":"Construction of an efficient evaluative instrument for myasthenia gravis: the MG composite","volume":"38","author":"Burns","year":"2008","journal-title":"Muscle Nerve"},{"key":"R28-8-20210206","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1212\/WNL.0b013e3181dc1b1e","article-title":"TM, Conaway MR, Sanders DB, on behalf of the MG composite MG-QOL 15 Study Group. The MG Composite. A valid and reliable outcome measure for myasthenia gravis.","volume":"74","year":"2010","journal-title":"Neurology"},{"key":"R29-8-20210206","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1212\/WNL.0b013e3181a41211","article-title":"Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals","volume":"72","author":"Alshekhlee","year":"2009","journal-title":"Neurology"},{"key":"R30-8-20210206","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1007\/s00415-009-5120-8","article-title":"Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up","volume":"256","author":"Kupersmith","year":"2009","journal-title":"J Neurol"},{"key":"R31-8-20210206","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1517\/14656560902950619","article-title":"Treatment strategies for myasthenia gravis","volume":"10","author":"Diaz-Manera","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"R32-8-20210206","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1586\/14737175.9.3.351","article-title":"Autoimmune myasthenia gravis","volume":"9","author":"Gilhus","year":"2009","journal-title":"Expert Rev Neurother"},{"key":"R33-8-20210206","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","article-title":"A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group","volume":"50","author":"Palace","year":"1998","journal-title":"Neurology"},{"key":"R34-8-20210206","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1212\/01.wnl.0000312373.67493.7f","article-title":"A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis.","volume":"71","year":"2008","journal-title":"Neurology"},{"key":"R35-8-20210206","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/mus.21640","article-title":"Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients","volume":"41","author":"Hehir","year":"2010","journal-title":"Muscle Nerve"},{"key":"R36-8-20210206","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/CND.0b013e31819a8403","article-title":"Rituximab for the treatment of thymoma-associated and de novo myasthenia gravis: 3 cases and review","volume":"10","author":"Nelson","year":"2009","journal-title":"J Clin Neuromuscul Dis"},{"key":"R37-8-20210206","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1468-1331.2008.02399.x","article-title":"Successful treatment of refractory generalized myasthenia gravis with rituximab","volume":"16","author":"Lebrun","year":"2009","journal-title":"Eur J Neurol"},{"key":"R38-8-20210206","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jns.2009.02.357","article-title":"Rituximab for myasthenia gravis: three case reports and review of the literature","volume":"280","author":"Stieglbauer","year":"2009","journal-title":"J Neurol Sci"},{"key":"R39-8-20210206","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2008.07.019","article-title":"B cell-targeted therapy with rituximab and autoimmune neuromuscular disorders","volume":"204","author":"St\u00fcbgen","year":"2008","journal-title":"J Neuroimmunol"},{"key":"R40-8-20210206","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/ana.21536","article-title":"Novel complement inhibitor limits severity of experimentally myasthenia gravis","volume":"65","author":"Soltys","year":"2009","journal-title":"Ann Neurol"},{"key":"R41-8-20210206","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.surg.2008.11.009","article-title":"Thymectomy is more effective than conservative treatment for myasthenia gravis regarding outcome and clinical improvement","volume":"145","author":"Bachmann","year":"2009","journal-title":"Surgery"},{"key":"R42-8-20210206","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jneuroim.2008.05.031","article-title":"The MGTX experience: challenges in planning and executing an international, multicenter clinical trial","volume":"201-202","author":"Aban","year":"2008","journal-title":"J Neuroimmunol"},{"key":"R43-8-20210206","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.athoracsur.2008.11.040","article-title":"Comparative clinical outcomes of thymectomy for myasthenia gravis performed by extended transsternal and minimally invasive approaches","volume":"87","author":"Meyer","year":"2009","journal-title":"Ann Thorac Surg"},{"key":"R44-8-20210206","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ejcts.2009.02.021","article-title":"Long-term outcome of thoracoscopic extended thymectomy for nonthymomatous myasthenia gravis","volume":"36","author":"Pompeo","year":"2009","journal-title":"Eur J Cardiothorac Surg"},{"key":"R45-8-20210206","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jneuroim.2008.07.012","article-title":"Thymoma-associated myasthenia gravis: outcome, clinical and pathological correlations in 197 patients on a 20-year experience","volume":"201\u2013202","author":"Maggi","year":"2008","journal-title":"J Neuroimmunol"},{"key":"R46-8-20210206","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.1200\/JCO.2008.20.6169","article-title":"SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: frequency and relation with survival","volume":"27","author":"Titulaer","year":"2009","journal-title":"J Clin Oncol"},{"key":"R47-8-20210206","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jneuroim.2008.05.024","article-title":"Paraneoplastic neurological autoimmunity and survival in small-cell lung cancer","volume":"201\u2013202","author":"Maddison","year":"2008","journal-title":"J Neuroimmunol"},{"key":"R48-8-20210206","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/mus.21422","article-title":"3,4-Diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS","volume":"40","author":"Oh","year":"2009","journal-title":"Muscle Nerve"},{"key":"R49-8-20210206","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/clpt.2009.35","article-title":"Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study","volume":"86","author":"Wirtz","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"R51-8-20210206","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/brain\/awh077","article-title":"Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis","volume":"127","author":"Vincent","year":"2004","journal-title":"Brain"},{"key":"R52-8-20210206","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1212\/01.WNL.0000122648.19196.02","article-title":"Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody","volume":"62","author":"Thieben","year":"2004","journal-title":"Neurology"},{"key":"R53-8-20210206","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1212\/01.wnl.0000326572.93762.51","article-title":"Immunotherapy-responsive seizure-like episodes with potassium channel antibodies","volume":"71","author":"Irani","year":"2008","journal-title":"Neurology"},{"key":"R54-8-20210206","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.bbagen.2007.10.001","article-title":"Antibodies against gangliosides and ganglioside complexes in Guillain-Barr\u00e9 syndrome: new aspects of research","volume":"1780","author":"Kusunoki","year":"2008","journal-title":"Biochim Biophys Acta"},{"key":"R55-8-20210206","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/brain\/awm316","article-title":"Eculizumab prevents antiganglioside antibody-mediated neuropathy in a murine model","volume":"131","author":"Halstead","year":"2008","journal-title":"Brain"},{"key":"R56-8-20210206","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1177\/039463200902200220","article-title":"Antibodies to ganglioside complexes in Guillain-Barr\u00e9 syndrome: clinical correlates, fine specificity and complement activation","volume":"22","author":"Notturno","year":"2009","journal-title":"Int J Immunopathol Pharmacol"},{"key":"R57-8-20210206","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jneuroim.2009.06.017","article-title":"Antibodies to ganglioside complexes consisting of asialo-GM1 and GQ1b or GT1a in Fisher and Guillain-Barr\u00e9 syndromes","volume":"214","author":"Ogawa","year":"2009","journal-title":"J Neuroimmunol"},{"key":"R58-8-20210206","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1136\/jnnp.2008.154765","article-title":"Cerebral glucose metabolism in Fisher syndrome","volume":"80","author":"Kim","year":"2009","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R59-8-20210206","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jns.2009.10.008","article-title":"Electrophysiological evidence of cerebellar fiber system involvement in the Miller Fisher syndrome","volume":"288","author":"Lo","year":"2010","journal-title":"J Neurol Sci"},{"key":"R60-8-20210206","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.expneurol.2009.03.009","article-title":"IgM anti-GQ1b monoclonal antibody inhibits voltage-dependent calcium current in cerebellar granule cells","volume":"219","author":"Nakatani","year":"2009","journal-title":"Exp Neurol"}],"container-title":["Current Opinion in Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/WCO.0b013e32833cc968","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:23:45Z","timestamp":1786040625000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00019052-201010000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":59,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/wco.0b013e32833cc968","relation":{},"ISSN":["1350-7540"],"issn-type":[{"value":"1350-7540","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}